Aiming to rebound from blunders years ago, Celldex touts a Phase Ib win with sights set on Xolair

Max Gelman

Senior Editor

Following multiple high-profile missteps several years ago, the folks over at Celldex Therapeutics began charting a path to redemption that would take on Roche and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aiming to rebound from blunders years ago, Celldex touts a Phase Ib win with sights set on Xolair

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Aim­ing to re­bound from blun­ders years ago, Celldex touts a Phase Ib win with sights set on Xo­lair

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Aiming to rebound from blunders years ago, Celldex touts a Phase Ib win with sights set on Xolair